ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.01B
1-Year Est. Return 174.02%
This Quarter Est. Return
1 Year Est. Return
+174.02%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$616M
AUM Growth
+$96.2M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
239
New
Increased
Reduced
Closed

Top Buys

1
+$52.1M
2
+$20.5M
3
+$14M
4
CTMX icon
CytomX Therapeutics
CTMX
+$6.89M
5
ABVX
Abivax
ABVX
+$6.59M

Top Sells

1
+$17.4M
2
+$8.63M
3
+$6.94M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.34M
5
AVR
Anteris Technologies
AVR
+$4.35M

Sector Composition

1 Healthcare 83.61%
2 Financials 2.95%
3 Consumer Discretionary 0%
4 Industrials 0%
5 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
201
BioCryst Pharmaceuticals
BCRX
$1.49B
– –
-10,000
AQN icon
202
Algonquin Power & Utilities
AQN
$4.66B
– –
-20,000
BNTX icon
203
BioNTech
BNTX
$24.8B
– –
-5,000
CKPT
204
DELISTED
Checkpoint Therapeutics
CKPT
– –
-305,800
CLRB icon
205
Cellectar Biosciences
CLRB
$12.3M
– –
-1,341
CRGX
206
DELISTED
CARGO Therapeutics
CRGX
– –
-341,515
DNTH icon
207
Dianthus Therapeutics
DNTH
$1.75B
– –
-18,285
EXAS icon
208
Exact Sciences
EXAS
$12.7B
– –
-5,000
IMNM icon
209
Immunome
IMNM
$1.57B
– –
-20,000
INMB icon
210
INmune Bio
INMB
$37.8M
– –
0
INSM icon
211
Insmed
INSM
$41.2B
– –
-6,074
IOVA icon
212
Iovance Biotherapeutics
IOVA
$981M
– –
-15,700
ISRG icon
213
Intuitive Surgical
ISRG
$195B
– –
-700
JWN
214
DELISTED
Nordstrom
JWN
– –
-12,000
KVACU icon
215
Keen Vision Acquisition Corp Units
KVACU
– –
-75,000
LYRA icon
216
Lyra Therapeutics
LYRA
$6.33M
– –
-10,664
MREO
217
Mereo BioPharma
MREO
$283M
– –
-10,000
NMRA icon
218
Neumora Therapeutics
NMRA
$443M
– –
-26,108
NVS icon
219
Novartis
NVS
$252B
– –
0
PTCT icon
220
PTC Therapeutics
PTCT
$6.05B
– –
-50,023
RLYB icon
221
Rallybio
RLYB
$27M
– –
-13,400
SLDB icon
222
Solid Biosciences
SLDB
$330M
– –
-34,479
TIL icon
223
Instil Bio
TIL
$97.3M
– –
-24,328
TNGX icon
224
Tango Therapeutics
TNGX
$1.1B
– –
-41,346
VYNE icon
225
VYNE Therapeutics
VYNE
$12.4M
– –
-70,419
6 7 8
9
10